Napabucasin Inhibits Proliferation and Migration of Glioblastoma Cells (U87) by Regulating JAK2/STAT3 Signaling Pathway

Basit Öğe Kaydı
dc.authoridTuncer, Mehmet Cudi/0000-0001-7317-5467
dc.contributor.authorUnlu, Ilker
dc.contributor.authorOzdemir, Ilhan
dc.contributor.authorTuncer, Mehmet Cudi
dc.date.accessioned2025-03-09T10:48:34Z
dc.date.available2025-03-09T10:48:34Z
dc.date.issued2024
dc.departmentİstanbul Beykent Üniversitesi
dc.description.abstractBackground and Objectives: Napabucasin (NP) was discovered as a natural compound that suppresses cancer stemness by inhibiting the signal transducer and activator of the transcription 3 (STAT3) signaling pathway. In this study, the anti-proliferative and apoptotic effects of NP and the chemotherapy agent doxorubicin (DX), a natural compound, on glioblastoma cells (U87) were investigated. Materials and Methods: In this study, the effects of NP and DX on cell viability on the glioblastoma U87 cell line were determined by MTT test. Expressions of Jak2/Stat3 genes were examined by qRT-PCR. Apoptosis was evaluated by Hoescht 33258 staining. Moreover, NP, its antagonistic-synergistic effects and IC50 doses of the combined treatment of DX were determined. Results: Napabucacin and doxorubicin were found to inhibit glioblastoma U87 cell proliferation. It was determined that NP applied in the range of 0.3-1 mu M and its combination with DX killed almost all of the glioblastoma cells in 48 h of application. Additionally, it was observed that Jak2/Stat3 expressions downregulated. Conclusions: These results show that NP suppresses the proliferation of glioblastoma cells. It was shown that the combination of NP and DX can prevent invasion of the U87 cell line due to its Jak2/Stat3 inhibitory effect. Since it can suppress Jak2/Stat3, an important cancer cell proliferation pathway in glioblastoma, the combination of NP and DX can be used as an alternative treatment agent. But no synergistic effect of NP and DX on the U87 cells of the glioblastoma cell line was observed.
dc.identifier.doi10.3390/medicina60101715
dc.identifier.issn1010-660X
dc.identifier.issn1648-9144
dc.identifier.issue10
dc.identifier.pmid39459502
dc.identifier.scopus2-s2.0-85207684570
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.3390/medicina60101715
dc.identifier.urihttps://hdl.handle.net/20.500.12662/4605
dc.identifier.volume60
dc.identifier.wosWOS:001342924700001
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherMDPI
dc.relation.ispartofMedicina-Lithuania
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WOS_20250310
dc.subjectglioblastoma doxorubicin
dc.subjectnapabucasin
dc.subjectStat3 inhibitory
dc.subjectMTT
dc.titleNapabucasin Inhibits Proliferation and Migration of Glioblastoma Cells (U87) by Regulating JAK2/STAT3 Signaling Pathway
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu